GlucoTrack Stock Technical Analysis
| GCTK Stock | USD 1.21 -0.06 -4.72% |
As of the 15th of March 2026, GlucoTrack is marked at 1.21 per share. Recent trend indicators show Risk Adjusted Performance of -0.24, standard deviation of 6.53, and Market Risk Adjusted Performance of -0.93. Trend analytics rely on normalized volatility and volume metrics. Trend metrics are reviewed within historical sector ranges.
GlucoTrack Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as GlucoTrack, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to GlucoTrackGlucoTrack | Build AI portfolio with GlucoTrack Stock |
Market capitalization and book value offer complementary views of GlucoTrack — the first driven by investor sentiment, the second by accounting standards. GlucoTrack's market capitalization is 1.22 M. A P/B ratio of 0.44 suggests GlucoTrack trades near or below book value. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for GlucoTrack are related but not identical, and they can diverge across cycles. For GlucoTrack, key inputs include a P/B ratio of 0.44, and ROE of -14.91%. By contrast, market price reflects the level where buyers and sellers transact.
What if' Analysis
Running a what-if backtest on GlucoTrack gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether GlucoTrack's historical reward profile was stable enough to support the current thesis.
| 12/15/2025 |
| 03/15/2026 |
A 0.00 position in GlucoTrack initiated on December 15, 2025 and held to today would record 0.00 in net gains. This reflects a 0.0% cumulative return in GlucoTrack in total across 90 days. GlucoTrack competes with or is related to Bone Biologics, ENDRA Life, Akanda Corp, Redhill Biopharma, InMed Pharmaceuticals, Bio Green, and Venus Concept. This provides context for relative positioning. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring device... More
Momentum Range Indicators for GlucoTrack Snapshot
Upside/downside measures for GlucoTrack frame directional pressure and range behavior. They provide a structured view of short-term momentum and range behavior.
| Information Ratio | -0.31 | |||
| Maximum Drawdown | 45.6 | |||
| Value At Risk | -10.40 | |||
| Potential Upside | 7.86 |
Volatility and Risk Indicators for GlucoTrack Snapshot
These indicators track GlucoTrack's volatility and return range dynamics. The signals are informational and describe volatility patterns.| Risk Adjusted Performance | -0.24 | |||
| Jensen Alpha | -1.97 | |||
| Total Risk Alpha | -1.70 | |||
| Treynor Ratio | -0.94 |
The degree to which GlucoTrack's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.24 | |||
| Market Risk Adjusted Performance | -0.93 | |||
| Mean Deviation | 4.56 | |||
| Coefficient Of Variation | -316.77 | |||
| Standard Deviation | 6.53 | |||
| Variance | 42.6 | |||
| Information Ratio | -0.31 | |||
| Jensen Alpha | -1.97 | |||
| Total Risk Alpha | -1.70 | |||
| Treynor Ratio | -0.94 | |||
| Maximum Drawdown | 45.6 | |||
| Value At Risk | -10.40 | |||
| Potential Upside | 7.86 | |||
| Skewness | -1.57 | |||
| Kurtosis | 7.51 |
GlucoTrack Backtested Returns
GlucoTrack registers an extremely high risk exposure across the specified investment window. It exhibits a Sharpe Ratio (Efficiency) of -0.32, indicating negative risk-adjusted returns over the last 3 months. Technical screening detected twenty-three indicators influencing risk dynamics. Please evaluate metrics such as standard deviation of 6.53, market risk-adjusted performance of -0.93, and risk-adjusted performance of -0.24 to validate implied downside exposure. The company owns a Beta (Systematic Risk) of 2.2, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GlucoTrack will likely underperform. At this point, GlucoTrack has a negative expected return of -2.07%. Please make sure to confirm GlucoTrack's relationship between the Accumulation Distribution and market facilitation index, to decide if GlucoTrack's performance from the past will be repeated in the future.
Auto-correlation | 0.81 |
Very good predictability
Serial correlation analysis for GlucoTrack reveals very good predictability across the intervals from 15th of December 2025 to 29th of January 2026 and from 29th of January 2026 to 15th of March 2026. The degree of alignment between past and current intervals shapes expectations about GlucoTrack's price persistence. At 0.81, around 81.0% of current GlucoTrack price movement aligns with historical price trajectory.
| Correlation Coefficient | 0.81 | |
| Spearman Rank Test | 0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Technical analysis for GlucoTrack evaluates price and volume patterns over time. Common inputs include moving averages, RSI, regressions, and price-return correlations.
Technical Analysis
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of GlucoTrack volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of GlucoTrack evaluates price structure, momentum, and volatility clustering. Breakout confirmation often requires sustained volume and liquidity depth. GlucoTrack has a market cap of 1.22 M, ROE of -14.91%.
Unless otherwise specified, data for GlucoTrack is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardGlucoTrack Technical Indicators
A technical review of GlucoTrack can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.24 | |||
| Market Risk Adjusted Performance | -0.93 | |||
| Mean Deviation | 4.56 | |||
| Coefficient Of Variation | -316.77 | |||
| Standard Deviation | 6.53 | |||
| Variance | 42.6 | |||
| Information Ratio | -0.31 | |||
| Jensen Alpha | -1.97 | |||
| Total Risk Alpha | -1.70 | |||
| Treynor Ratio | -0.94 | |||
| Maximum Drawdown | 45.6 | |||
| Value At Risk | -10.40 | |||
| Potential Upside | 7.86 | |||
| Skewness | -1.57 | |||
| Kurtosis | 7.51 |
March 15, 2026 Daily Trend Indicators
A technical review of GlucoTrack can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 0.13 | ||
| Daily Balance Of Power | -0.38 | ||
| Rate Of Daily Change | 0.95 | ||
| Day Median Price | 1.19 | ||
| Day Typical Price | 1.20 | ||
| Price Action Indicator | -0.01 | ||
| Market Facilitation Index | 0.16 |
More Resources for GlucoTrack Stock Analysis
A structured review of GlucoTrack often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for GlucoTrack Stock. Highlighted below are reports that provide context for GlucoTrack Stock:GlucoTrack has a market cap of 1.22 M, ROE of -14.91%. Risk vs Return Analysis can help frame allocation decisions. The allocation includes a position in GlucoTrack inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Explore our How to Trade GlucoTrack Stock guide to learn how to trade GlucoTrack effectively.Analysis related to GlucoTrack should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Market capitalization and book value offer complementary views of GlucoTrack — the first driven by investor sentiment, the second by accounting standards. GlucoTrack's market capitalization is 1.22 M. A P/B ratio of 0.44 suggests GlucoTrack trades near or below book value. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for GlucoTrack are related but not identical, and they can diverge across cycles. For GlucoTrack, key inputs include a P/B ratio of 0.44, and ROE of -14.91%. By contrast, market price reflects the level where buyers and sellers transact.